Cencora, Inc. (COR) Stock Price & Analysis
Cencora, Inc. (COR) fell 1.86% to USD 330.95 as of September 8, 2026 at 02:49 UTC, according to Nexqual real-time market data.
COR last closed at USD 337.22; the session ranged USD 330.2–336.01 on volume of 1,017,372 shares. Market capitalization is $63.15B, with a 52-week range of USD 244.82–377.54 (NYQ). Source: Nexqual, September 8, 2026 at 02:49 UTC.
Key Statistics (as of September 8, 2026 at 02:49 UTC)
| Price | USD 330.95 |
|---|---|
| Change | ▼ 1.86% (down) |
| Previous Close | USD 337.22 |
| Open | USD 333.48 |
| Day Range | USD 330.2 – 336.01 |
| 52-Week Range | USD 244.82 – 377.54 |
| Volume | 1,017,372 shares |
| Market Cap | $63.15B |
| Exchange | NYQ |
Technical Analysis (COR)
Nexqual's technical model rates COR "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 02:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.79 (neutral) |
| vs SMA50 | Above (USD 312.1) |
| MACD | 6.04 (positive) |
Analyst Ratings (COR)
Wall Street analysts rate COR "Buy" based on 13 analysts, with a mean price target of USD 369.31 (range USD 330–430), per Nexqual as of September 8, 2026 at 02:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 369.31 |
| High Target | USD 430 |
| Low Target | USD 330 |
| Buy / Hold / Sell | 11 / 4 / 0 |
Earnings (COR)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 4.56 |
| Revenue Estimate | $88.11B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 4.48 vs est 4.35 ▲ beat |
| 2026-03-31 | USD 4.75 vs est 4.72 ▲ beat |
| 2025-12-31 | USD 4.08 vs est 4.04 ▲ beat |
| 2025-09-30 | USD 3.84 vs est 3.79 ▲ beat |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
Financials & Fundamentals (COR)
| Total Revenue | $332.77B |
|---|---|
| Revenue Growth (YoY) | +5.10% |
| Gross Margin | +3.96% |
| Operating Margin | +1.41% |
| Profit Margin | +0.79% |
| ROE | +96.87% |
| Debt / Equity | 446.52 |
| Current Ratio | 0.94 |
| Total Cash | $2.82B |
| Total Debt | $14.46B |
| Free Cash Flow | $2.04B |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
Financial Health Score (COR)
Nexqual rates Cencora, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 02:49 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 4%, operating 1% |
| Balance Sheet | Critical — $2.82B cash vs $14.5B debt |
| Cash Flow | Mixed — FCF $2.04B, slim 0.6% margin |
| Efficiency | Strong — ROE 97%, ROA 3.6% |
Ownership (COR)
| Insider Ownership | +4.30% |
|---|---|
| Institutional Ownership | +99.74% |
| Shares Outstanding | 190.83M |
| Float | 180.25M |
| Short % of Float | +2.77% |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
Leadership (COR)
Cencora, Inc. is led by Robert P. Mauch Ph.D., PharmD (age 58), President, CEO & Director, per Nexqual as of September 8, 2026 at 02:49 UTC.
| President, CEO & Director | Robert P. Mauch Ph.D., PharmD (age 58) |
|---|---|
| Executive VP & CFO | Eva C. Boratto (age 58) |
| EVP and President of U.S. Pharmaceuticals & Animal Health | Richard Tremonte |
Major Backers & Investors (COR)
Notable institutional backers of Cencora, Inc. include T. Rowe Price, Price (T.Rowe) Associates Inc, JPMorgan, according to Nexqual as of September 8, 2026 at 02:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 6.21% |
| Price (T.Rowe) Associates Inc | 4.59% |
| JPMorgan | 3.11% |
| Boston Partners | 2.55% |
| Wellington Management | 2.39% |
| Fidelity | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.56% |
| BlackRock | 10.94% |
| State Street | 6.11% |
| Geode Capital | 2.86% |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
From Cencora, Inc.'s Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
- Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DLR | Digital Realty Trust, Inc. | USD 188.39 | ▲ 2.52% |
| EQIX | Equinix, Inc. | USD 1,035.98 | ▲ 1.64% |
| EXR | Extra Space Storage Inc | USD 139.25 | ▼ 0.49% |
| CPT | Camden Property Trust | USD 105.69 | ▲ 0.14% |
| ARE | Alexandria Real Estate Equities | USD 52.65 | ▼ 0.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:49 UTC. This page is informational and not investment advice.